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Abstract
Objectives To evaluate the prognostic relevance of temporal
muscle thickness (TMT) in brain metastasis patients.
Methods We retrospectively analysed TMT on magnetic res-
onance (MR) images at diagnosis of brain metastasis in two
independent cohorts of 188 breast cancer (BC) and 247 non-
small cell lung cancer (NSCLC) patients (overall: 435
patients).
Results Survival analysis using a Cox regression model
showed a reduced risk of death by 19% with every additional
millimetre of baseline TMT in the BC cohort and by 24% in
the NSCLC cohort. Multivariate analysis included TMT and
diagnosis-specific graded prognostic assessment (DS-GPA) as
covariates in the BC cohort (TMT: HR 0.791/CI [0.703–
0.889]/p < 0.001; DS-GPA: HR 1.433/CI [1.160–1.771]/p =
0.001), and TMT, gender and DS-GPA in the NSCLC cohort
(TMT: HR 0.710/CI [0.646–0.780]/p < 0.001; gender: HR
0.516/CI [0.387–0.687]/p < 0.001; DS-GPA: HR 1.205/CI
[1.018–1.426]/p = 0.030).
Conclusion TMT is easily and reproducibly assessable on
routineMR images and is an independent predictor of survival
in patients with newly diagnosed brain metastasis from BC
and NSCLC. TMT may help to better define frail patient pop-
ulations and thus facilitate patient selection for therapeutic
measures or clinical trials. Further prospective studies are
needed to correlate TMTwith other clinical frailty parameters
of patients.
Key Points
• TMT has an independent prognostic relevance in brain me-
tastasis patients.
• It is an easily and reproducibly parameter assessable on
routine cranial MRI.
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• This parameter may aid in patient selection and stratifica-
tion in clinical trials.
• TMT may serve as surrogate marker for sarcopenia.
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BMI Body mass index
CT Computed tomography
DS-GPA Diagnosis-specific graded prognostic assessment
ICC Intraclass correlations
MRI Magnetic resonance imaging
NSCLC Non-small cell lung cancer
OS Overall survival
TMT Temporal muscle thickness
Introduction
Brain metastases are a frequent occurrence, and affect up to
40% of cancer patients during their disease course. Primary
tumour types differ in their tendency to spread to the CNS,
with non-small cell lung cancer (NSCLC) and breast cancer
(BC) showing the highest frequency of brain metastases in the
clinical setting [1, 2]. Brain metastases are associated with a
significant symptom burden, a reduced quality of life, and
poor survival times. Therapy strategies include neurosurgical
resection, radiation therapy (whole-brain radiotherapy or
stereotactic radiosurgery) and systemic therapies depending
on the number, location and size of CNS lesions, the extracra-
nial disease status, the patient’s clinical condition and histo-
logical and molecular tumour characteristics [3].
Brain metastases as a result of NSCLC and BC are gener-
ally considered incurable and are associated with poor median
overall survival times. However, individual survival times
show a high variability and range from 3 to 14.8 months in
NSCLC and 3.4 to 25.3 months in BC patients with brain
metastases [4, 5]. Established prognostic scores consider clin-
ical factors, such as the number of brain metastases, the extra-
cranial tumour status and the Karnofsky performance scale for
outcome prediction. However, recently scores based solely on
these clinical characteristics were shown to lack accuracy in
survival prediction [6]. In particular, the assessment of the
patient’s physical capacity is based on the subjective judge-
ment of the attending physician and is prone to observer var-
iability [7]. More objective measures of the patient’s physical
condition may help to improve outcome prediction.
Cancer-related cachexia has been defined by international
consensus as a syndrome that consists of skeletal muscle mass
loss, which leads to progressive functional impairment with-
out the possibility of complete reversal by conventional nutri-
tional support [8]. In addition to weight loss, sarcopenia,
which is defined as a loss of skeletal muscle mass and func-
tion, has a core role in cancer-related cachexia [8]. Due to its
association with disability and functional impairment,
sarcopenia can be used as an objectively measurable parame-
ter of frailty. Recent studies revealed a high correlation be-
tween sarcopenia and reduced long-term outcome in several
cancer types [9, 10]. The majority of these observations were
based on skeletal muscle index cut-offs determined by the
total cross-sectional skeletal muscle area at the level of the
third lumbar vertebra, using computed tomography (CT)
scans [9, 11]. Moreover, the cross-sectional area of the psoas
muscle at the level of lumbar vertebra L3 has also been deter-
mined to be a reliable marker of sarcopenia, thus increasing
the practicality of the measurement in the routine clinical set-
ting [12]. A recent study revealed a high correlation between
the psoas muscle area and temporal muscle thickness (TMT),
indicating that not only abdominal muscles but also craniofa-
cial muscles are useful as indicators of patient frailty [13]. This
would be advantageous, especially in patients with brain tu-
mours, because TMT can be evaluated on routine brain CT or
magnetic resonance imaging (MRI) examinations. We thus
hypothesize that TMT may serve as a surrogate marker of
patient frailty that can easily be measured on standard MR
images in brain tumour patients. We have, therefore, investi-
gated the prognostic relevance of TMT in two large and inde-
pendent series of BC and NSCLC brain metastasis patients.
Methods
Patients
All patients treated for newly diagnosed brain metasta-
ses from either BC or NSCLC at the Medical University
of Vienna between 2008 and 2013 were identified from
a brain metastasis database (n = 501). Sixty-six patients
were excluded because: (a) MRI images were not re-
trievable (n = 26), (b) only CT images of the brain were
available (n = 31) or (c) images were inaccurate due to
motion artifacts (n = 9). Clinical data, including informa-
tion on the primary tumour, clinical course and survival
times, were retrieved by chart review. The diagnosis-
specific graded prognostic assessment (DS-GPA) is an
established and validated clinical prognostic assessment
based on various clinical factors. Importantly, the in-
cluded clinical factors differ depending on the underly-
ing primary tumour type. In NSCLC the DS-GPA is
calculated based on age, number of brain metastasis,
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Karnofsky performance status and presence of extracra-
nial metastases. In breast cancer the DS-GPA includes
age, breast cancer subtype and Karnofsky performance
status. DS-GPA calculation was applied as previously
described by Sperduto et al. [5].The ethics committee
of the Medical University of Vienna approved the study
(Vote 078/2004).
Analyses of temporal muscle thickness (TMT)
Baseline TMT at diagnosis of brain metastasis was mea-
sured on the axial plane of isovoxel (1 × 1 × 1 mm) T1-
weighted MR images perpendicular to the long axis of
the temporal muscle at the level of the orbital roof.
Axial MR plane was oriented parallel to the anterior
commissure–posterior commissure line. The Sylvian fis-
sure defined a reference point regarding the anterior-
posterior orientation. These landmarks were defined be-
fore all TMT measurements to increase the accuracy of
TMT measurement in each patient. In all patients, TMT
on the left and on the right side were determined sepa-
rately. One board-certified radiologist (JF, the main ob-
server) analysed TMT for all included patients. For the
BC data only female patients were included. Examples
of TMT assessment on MR images are illustrated in
Fig. 1. Both subcohorts (120/188 BC; 120/247
NSCLC) were evaluated by one additional, independent
board-certified radiologist blinded to the results of the
main observer and to all clinical characteristics.
Intraclass correlations (ICC) were estimated to assess
intra-observer reliability using a two-way mixed model
for both sub-cohorts respectively. Values were
interpreted as no agreement for values <0, as slight
agreement for 0–0.20, as fair for 0.21–0.40, as moderate
for 0.41–0.60, as substantial for 0.61–0.80, and as al-
most perfect agreement for 0.81–1.
Statistical analysis
Overall survival (OS) was defined as from the diagnosis of
brain metastasis to death or date of last follow-up. Median
TMTwas assessed by summing the measurements from each
side and then dividing by two, which resulted in one variable –
the median TMT per patient. TMTwas grouped according to
the median per group and the Kaplan Meier product was ap-
plied to retrieve survival curves. The log-rank test was used to
investigate differences between groups. TMTwas entered as a
scale variable in a Cox regression model to investigate the
association with survival times. The Spearman correlation co-
efficient was used to correlate two scale variables. A
Spearman correlation coefficient from (-)0.7 to (-)1 was
regarded as a strong association, a correlation coefficient of
(-)0.5 to (-)0.7 as moderate, and a correlation coefficient of
(-)0.3 to (-)0.5 as a low association. A Spearman correlation
coefficient of 0 to (-)0.3 was interpreted as no association. A
two-tailed p-value of <0.05 was considered statistically sig-
nificant. Due to the hypothesis-generating approach of the




Two independent cohorts consisting of 188 patients with new-
ly diagnosed brain metastasis from BC (BC cohort) and 247
patients with newly diagnosed brain metastasis from NSCLC
Fig. 1 Magnetic resonance
images representing temporal
muscle thickness (TMT) assess-
ment. (A) A 58-year-old male
patient with an overall survival of
59 months (median TMT =
11.2 mm), and (B) a 68-year-old
male patient with an overall sur-
vival of 1 month (median TMT =
4.6 mm)
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(NSCLC cohort) were available for further analysis.
Therefore, overall, 435 patients were included in the final
analysis. Patient characteristics, including clinical characteris-
tics, survival times and applied therapies are provided as
Supplemental Table 1.
Assessment of TMTand observer agreement
The median TMT on the right side was 5.3 mm (range 1.1–
10.6), and 5.4 mm (range 1.2–11.0) on the left side, resulting
in a median of 5.4 mm (range 1.6–10.5) in the BC cohort. In
the NSCLC cohort, the median TMT on the right side was
6.0 mm (range 2.1–11.0), and 5.8 mm (range 2.0–12.8) on
the left side, resulting in a median of 5.9 mm (range 2.2–
11.0) in this group.
Inter-observer reliability was assessed and revealed almost
perfect agreement between both observers for NSCLC (n =
120 patients, ICC = 0.995, CI 0.993–0.996, p < 0.001) and BC
(n = 120 patients, ICC = 0.996, CI 0.995–0.997, p < 0.001)
sub-cohorts (Supplemental Fig. 1). Based on this almost per-
fect agreement between both observers in the two sub-cohorts,
TMTcalculations were, as described in the Statistical analysis
section, based on the measurements of the main observer for
the final analysis including 435 (188 BC, 247 NSCLC)
patients.
Correlation of TMTwith clinical characteristics
in the breast cancer (BC) cohort
Median TMT showed a low negative correlation with age at
diagnosis of brain metastasis (Spearman correlation coeffi-
cient -0.324; p < 0.001). Further, there was no correlation be-
tween median TMT and median time from diagnosis of pri-
mary tumour to diagnosis of brain metastasis (Spearman cor-
relation coefficient -0.043; p = 0.554), bodymass index (BMI)
(Spearman correlation coefficient -0.164; p = 0.265) or corti-
sone treatment at diagnosis of brain metastasis (p = 0.108).
Correlation of TMTwith clinical characteristics
in the non-small cell lung cancer (NSCLC) cohort
Age at diagnosis of brain metastasis showed a low negative
correlation with median TMT (Spearman correlation coeffi-
cient -0.271; p < 0.001). Median TMTwas significantly lower
in female patients (5.2 mm) compared to male patients
(6.3 mm) (p < 0.001; Mann-Whitney U test). However, medi-
an TMT in the female BC and NSCLC cohort showed no
significant difference (p = 0.245; t-test). As already observed
in the BC cohort, there was no strong correlation between
median TMT and median time from diagnosis of primary tu-
mour to diagnosis of brain metastasis (Spearman correlation
coefficient 0.008; p = 0.901), BMI (Spearman correlation
coefficient 0.292; p < 0.001) or cortisone treatment (p =
0.493; Mann-Whitney U test).
Correlation of median TMTwith survival time
from the diagnosis of brain metastasis in the BC cohort
Survival analysis, using a Cox regression model, was per-
formed with baseline TMT diameters to predict survival time
in the BC cohort. Here, patients with a higher baseline TMT
had an improved survival prognosis with a hazard ratio (HR)
of 0.810 (95% CI 0.736–0.892; p < 0.001; Cox regression
model). Explicitly, the risk of death was reduced by 19% with
every additional millimetre of baseline TMT. Patients with
TMT >median (19 months) had a statistically significant lon-
ger survival time compared to patients with TMT <median
(5 months; p < 0.001; log-rank test; Fig. 2A).
Further analysis was performed with a Cox regression
model that included TMT and DS-GPA as covariates. In the
Fig. 2 Overall survival according to median temporal muscle thickness
(TMT). (A) Breast cancer (BC) cohort; (B) non-small cell lung cancer
(NSCLC) cohort. Cum cumulative
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multivariate model, TMT (HR 0.791; 95% CI 0.703–0.889; p
< 0.001;) as well as DS-GPA (HR 1.433; 95% CI 1.160–
1.761; p = 0.001) showed a statistically significant association
with survival prognosis. Explicitly, TMT prediction of surviv-
al was nearly unchanged, with a reduced risk of death of 21%
with every additional millimetre of baseline TMT.
Correlation of TMTwith survival time from the diagnosis
of brain metastasis in the NSCLC cohort
A survival analysis using a Cox regression model was per-
formed with baseline TMT diameters to predict survival time
in the NSCLC cohort. Similar to the findings in the BC cohort,
TMT was statistically significantly associated with survival
prognosis with an HR of 0.754 (95% CI 0.692–0.821; p <
0.001; Cox regression model). Explicitly, the risk of death
was reduced by 24% with every additional millimetre of base-
line TMT. Patients with a TMT >median (15months) present-
ed with a statistically significant longer survival time com-
pared to patients with TMT (5 months; p < 0.001; log rank
test; Fig. 2B).
To assess the independence of TMT in the NSCLC cohort,
further analysis was performed, using a Cox regression model
that included TMTand clinical factors shown to be associated
with TMT, such as gender and DS-GPA. In the multivariate
model, TMT (HR 0.710; 95%CI 0.646–0.780; p < 0,001; Cox
regression model) as well as gender (HR 0.516; 95% CI
0.387–0.687; p < 0.001) and DS-GPA (HR 1.205; 95% CI
1.018–1.426; p = 0.030) showed a statistically significant as-
sociation with survival prognosis. Explicitly, TMT prediction
of survival was stable, with a reduced risk of death of 29%,
with every additional millimetre of TMT.
Discussion
This study aimed to investigate the prognostic role of TMT
measured on routinely obtained MR images of the brain in
patients with brain metastases. We selected clearly defined
patient cohorts of the most common tumour types that are
responsible for CNS spread, and included only patients with
full clinical follow-up and availability of adequate cranial
MRIs at the diagnosis of brain metastasis. We found a strong
correlation of TMTwith patient prognosis, as each millimetre
of baseline TMT reduced the risk of death by 19% in the BC
cohort and by 24% in the NSCLC cohort. Importantly, the
effect was independent of established prognostic factors. We
thus feel that TMT measurement can help to improve the
survival prediction of brain metastasis patients in the clinical
setting, and may aid in patient selection and stratification in
clinical trials.
The temporal muscle was chosen as the muscle of interest
for our study because it is one of the few easily measurable
craniofacial muscles, which is assessed in its entire expanse on
routinely obtained brain MR images. Kilgour et al. [15] sug-
gested the use of cross-sectional areas of neck muscles at the
midpoint level of C2 to investigate the age-related loss of
muscle mass on brain MR scans. However, a limitation of this
technique is that these muscles are, in most cases, only incom-
pletely depicted on routine cranial MR images. In our case
series, the neck muscles were not evaluable according to the
algorithm of Kilgour et al. in the vast majority of cases. For
our study, we used a clear and easily reproducible algorithm to
measure TMT with defined anatomical landmarks, and
showed excellent inter-rater reliability for this approach.
TMT measurement per case took only approximately 30 s
per patient, and can, in our experience, easily be incorporated
into the clinical workflow.
Our findings are in line with the published literature, as
muscle loss has been shown to be a strong adverse prognostic
factor in other cancer types, but has, to our knowledge, not
been investigated in brain metastasis patients [9, 10]. Cancer-
associated cachexia has a multi-factorial aetiology and may be
related to insufficient nutrition, catabolic metabolism,
paraneoplastic effects, chronic inflammation, anti-neoplastic
therapies and other factors [8]. We did not investigate the
specific pathobiology of temporal muscle-wasting in our
study, but we consider it likely to be reflective of a generalized
cancer-associated sarcopenic state. This notion is supported
by a previous study that showed a good correlation between
skeletal muscle and TMT [13]. Of note, we did not find a
correlation between corticosteroid intake at the diagnosis of
brain metastasis and TMT. Corticosteroids are known to lead
to significant muscle loss over time; however, they are usually
prescribed in cases of symptomatic brain oedema in patients
with known brain metastases. We measured baseline TMT at
the time of brain metastasis diagnosis in our study, and, there-
fore, patients were unlikely to have been exposed to cortico-
steroids for a prolonged period of time.
We performed correlations with some patient characteris-
tics and the results of these analyses show that TMTmeasure-
ment provides information not captured by other clinical pa-
rameters. First, we found only a weak inverse correlation of
TMT with patient age. This finding indicates that measure-
ment of sarcopenia as an indicator of the patient’s physical
condition may be more informative for clinical decision-
making than consideration of the chronological age alone.
Furthermore, we found no correlation between TMT and
BMI. This finding may be explained by the fact that the
BMI does not differentiate between lean body mass and fat
mass, and TMT measurement is more likely to be sensitive to
sarcopenic obesity (low-muscle-obesity) [9]. The fact that the
median TMT varies between the NSCLC and the BC patient
cohort is based on the difference in gender predominance
within these two cohorts. The NSCLC patient cohort
consisted of male and female patients in comparison to the
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BC cohort, which included only female patients. As expected,
we observed significantly higher TMT values in male than in
female patients. Still, the prognostic role of TMT was inde-
pendent of patient gender in the NSCLC cohort. Male BC
patients are exceedingly rare and were excluded from our
study.
Some limitations of our study need to be acknowledged.
Due to the retrospective nature of our investigation, we were
not able to correlate TMT with muscle strength or actual pa-
tient frailty. In order to study such functional-anatomical rela-
tionships, prospective studies need to be designed.
Furthermore, although a correlation between TMT and skele-
tal muscle measurements was established in a prior study [13],
we were unable to confirm this association in our series. We
could not, unfortunately, retrieve a sufficient number of CT
scans of the abdomen from our patients, as these had been
performed at external institutions in most cases. However,
we were able to confirm the prognostic role of TMT in two
independent and large patient cohorts, and thus feel that our
data provide strong evidence that warrants further investiga-
tion of TMT and its clinical applications. The advantage that
the temporal muscle is completely depicted on routine MRI
scans and is therefore suitable to reflect muscle mass loss on
this image modality comes with the disadvantage that it is a
relatively small muscle regarding muscle diameter. To in-
crease the measurement accuracy a precise measurement (in-
cluding image magnification) as well as a strict adherence to
the predefined landmarks for TMT measurements are crucial.
Further studies may also investigate whether TMT has prog-
nostic relevance in other brain tumour types, including brain
metastases from other cancers, as well as primary brain tu-
mours, such as gliomas.
Moreover, patients without a full clinical follow-up includ-
ing further applied therapies and characteristics of the clinical
course were excluded from the analysis to limit the analysis to
a rather homogenous cohort of patients with comparable treat-
ment approaches, all primarily treated at our centre. Excluded
patients mainly encompassed patients majorly treated at a dif-
ferent centre, especially in nearby countries, who were only
transferred to the Medical University of Vienna for the treat-
ment of newly diagnosed brain metastasis. Importantly, fragile
patients were therefore more likely to be included in the fur-
ther analysis as their treatment stayed within our tertiary care
centre to adequately address all symptoms. Nevertheless, our
data need to be validated in a prospective setting.
The awareness of the relationship between the loss of mus-
cle mass and cancer outcome may lead to new therapeutic
targets. Muscle loss in cancer patients is considered to be a
multifactorial event involving mainly inflammatory but also
catabolic processes. Thus, nutrition alone has not been able to
reverse muscle-wasting in cancer patients. Recent trials have
focused on the prevention of cancer-related sarcopenia, in-
cluding exercise training [16], nutritional supplements like
omega-3 fatty acids [17] or medication-based concepts such
as myostatin inhibitors [18] or melanocortin-4 receptor antag-
onists [19]. It is, therefore, all the more important to include
muscle mass assessment in the routine clinical setting of can-
cer patients to recognize the onset of muscle mass loss so that
interventions to improve or delay the progression of this pro-
cess can be implemented.
In conclusion, our data show that TMT is a reproducibly
assessable parameter that allows survival prediction in pa-
tients with brain metastases. TMT may help to better define
frail patient populations and may optimize patient selection
for therapeutic measures or clinical trials. However, further
prospective studies are needed to correlate TMT with other
clinical frailty parameters of the patients.
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